Bard wins FDA panel date for Lutonix balloon

The FDA's Circulatory System Devices advisory panel is slated to review C.R. Bard's Lutonix drug-eluting balloon next month.

C.R. Bard (NYSE:BCR) won a date for an FDA panel review next for its Lutonix drug-eluting balloon in treating peripheral artery disease, ahead of its bid for approval to put the device on the U.S. market.

C.R. Bard, Food & Drug Administration (FDA)

News Well, Peripheral Artery Disease, Pre-Market Approval (PMA), Regulatory/Compliance

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1nbELtz